Login to Your Account

Clinuvel Filing for Scenesse in EU on Phase III Data in EPP

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 21, 2011
Clinuvel Pharmaceuticals Ltd. plans to complete a European regulatory filing for its lead drug Scenesse (afamelanotide) in the coming weeks, following a Phase III trial in patients with erythropoietic protoporphyria (EPP), which met its primary endpoint.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription